[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.]
[L02BA01, tamoxifen, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tamoxifen.]
[L01CB02, teniposide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Teniposide.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Thalidomide.]
[L01XF01, tretinoin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tretinoin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belimumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipilimumab.]
[L01CA01, vinblastine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vindesine.]
[M05BA03, pamidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Tiludronic acid.]
[M05BA06, ibandronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.]
[L03AB11, peginterferon alfa-2a, The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Bevacizumab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bevacizumab.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Pertuzumab.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raxibacumab.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Benzocaine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Benzyl alcohol.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siltuximab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ramucirumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vedolizumab.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pembrolizumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dulaglutide.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blinatumomab.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nivolumab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Secukinumab.]
[L01DC01, bleomycin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Bleomycin.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Alirocumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evolocumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarucizumab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asfotase alfa.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mepolizumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daratumumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Elotuzumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetanus immune globulin, human.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixekizumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Reslizumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obiltoxaximab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Atezolizumab.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Arsenic trioxide.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaratumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brodalumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Avelumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ocrelizumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dupilumab.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Durvalumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Capecitabine.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inotuzumab ozogamicin.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emicizumab.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Bevacizumab.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Capsaicin.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Erenumab.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab emtansine.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Antilymphocyte immunoglobulin (horse).]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mogamulizumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galcanezumab.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Carmustine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Caplacizumab.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Romosozumab.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Risankizumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brolucizumab.]
[L01FD01, trastuzumab, The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Bevacizumab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab deruxtecan.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sacituzumab govitecan.]
[L04AA47, inebilizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Dyclonine.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belantamab mafodotin.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Bevacizumab.]
[L01BB05, fludarabine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Fludarabine.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Margetuximab.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amivantamab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sotrovimab.]
[L01XA01, cisplatin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cisplatin.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aducanumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anifrolumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tisotumab vedotin.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sutimlimab.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Levobupivacaine.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Spesolimab.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tremelimumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ublituximab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panitumumab.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hepatitis B immune globulin.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Bevacizumab.]
[L01EA01, imatinib, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Imatinib.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bevacizumab.]
[L01AA01, cyclophosphamide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cyclophosphamide.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab.]
[L01DB02, daunorubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Daunorubicin.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Bevacizumab.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Cinchocaine.]
[M05BA02, clodronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Clodronic acid.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Bevacizumab.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Bevacizumab.]
[C01AA04, digitoxin, Digitoxin may decrease the cardiotoxic activities of Bevacizumab.]
[C01AA05, digoxin, Digoxin may decrease the cardiotoxic activities of Bevacizumab.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Bevacizumab.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Pramocaine.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Bevacizumab.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Diphenhydramine.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human Rho(D) immune globulin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Natalizumab is combined with Bevacizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.]
[L01XG01, bortezomib, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Bortezomib.]
[L01DB01, doxorubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Doxorubicin.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Bevacizumab.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human varicella-zoster immune globulin.]
[L01CA04, vinorelbine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vinorelbine.]
[L01DB03, epirubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Epirubicin.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Bevacizumab.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Bevacizumab.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Bevacizumab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Bevacizumab.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Bevacizumab.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Etoposide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.]
[L04AA40, cladribine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cladribine.]
[L01BC02, fluorouracil, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Fluorouracil.]
[M05BA04, alendronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.]
[M05BA07, risedronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Risedronic acid.]
[L01DB06, idarubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Ifosfamide.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.]
[L01CD01, paclitaxel, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Articaine.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ranibizumab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tocilizumab.]
[L01DC03, mitomycin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Mitomycin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Lidocaine.]
[L01AA05, mechlorethamine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Mechlorethamine.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Bevacizumab.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Mepivacaine.]
[L04AX03, methotrexate, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Methotrexate.]
[L01DB07, mitoxantrone, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Mitoxantrone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ofatumumab.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab.]
[L01CD02, docetaxel, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Docetaxel.]
[L01XX01, amsacrine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Amsacrine.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Bevacizumab.]
[M05BA08, zoledronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Zoledronic acid.]
[L01XX08, pentostatin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Pentostatin.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Edrecolomab.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Golimumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ustekinumab.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Canakinumab.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Procaine.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Bevacizumab.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Denosumab.]
[L01CD04, cabazitaxel, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cabazitaxel.]
[M05BA01, etidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Etidronic acid.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.]
[L02BA01, tamoxifen, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tamoxifen.]
[L01CB02, teniposide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Teniposide.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Thalidomide.]
[L01XF01, tretinoin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tretinoin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belimumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipilimumab.]
[L01CA01, vinblastine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vindesine.]
[M05BA03, pamidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Tiludronic acid.]
[M05BA06, ibandronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.]
[L03AB11, peginterferon alfa-2a, The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Bevacizumab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bevacizumab.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Pertuzumab.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raxibacumab.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Benzocaine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Benzyl alcohol.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siltuximab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ramucirumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vedolizumab.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pembrolizumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dulaglutide.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blinatumomab.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nivolumab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Secukinumab.]
[L01DC01, bleomycin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Bleomycin.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Alirocumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evolocumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarucizumab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asfotase alfa.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mepolizumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daratumumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Elotuzumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetanus immune globulin, human.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixekizumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Reslizumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obiltoxaximab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Atezolizumab.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Arsenic trioxide.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaratumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brodalumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Avelumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ocrelizumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dupilumab.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Durvalumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Capecitabine.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inotuzumab ozogamicin.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emicizumab.]
[C01AA02, acetyldigoxins, Acetyldigoxin may decrease the cardiotoxic activities of Bevacizumab.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Capsaicin.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Erenumab.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mogamulizumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galcanezumab.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Carmustine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Caplacizumab.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Romosozumab.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Risankizumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brolucizumab.]
[L01FD01, trastuzumab, The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Bevacizumab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab deruxtecan.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab emtansine.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sacituzumab govitecan.]
[L04AA47, inebilizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Dyclonine.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belantamab mafodotin.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Bevacizumab.]
[L01BB05, fludarabine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Fludarabine.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Margetuximab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Antilymphocyte immunoglobulin (horse).]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amivantamab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sotrovimab.]
[L01XA01, cisplatin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cisplatin.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aducanumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anifrolumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tisotumab vedotin.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sutimlimab.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Levobupivacaine.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Spesolimab.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tremelimumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ublituximab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panitumumab.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hepatitis B immune globulin.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Bevacizumab.]
[L01EA01, imatinib, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Imatinib.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bevacizumab.]
[L01AA01, cyclophosphamide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cyclophosphamide.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab.]
[L01DB02, daunorubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Daunorubicin.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Bevacizumab.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Cinchocaine.]
[M05BA02, clodronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Clodronic acid.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Bevacizumab.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Bevacizumab.]
[C01AA04, digitoxin, Digitoxin may decrease the cardiotoxic activities of Bevacizumab.]
[C01AA05, digoxin, Digoxin may decrease the cardiotoxic activities of Bevacizumab.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Bevacizumab.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Pramocaine.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Bevacizumab.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Diphenhydramine.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human Rho(D) immune globulin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Natalizumab is combined with Bevacizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.]
[L01XG01, bortezomib, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Bortezomib.]
[L01DB01, doxorubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Doxorubicin.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Bevacizumab.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human varicella-zoster immune globulin.]
[L01CA04, vinorelbine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vinorelbine.]
[L01DB03, epirubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Epirubicin.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Bevacizumab.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Bevacizumab.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Bevacizumab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Bevacizumab.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Bevacizumab.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Etoposide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.]
[L04AA40, cladribine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cladribine.]
[L01BC02, fluorouracil, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Fluorouracil.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.]
[M05BA07, risedronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Risedronic acid.]
[L01DB06, idarubicin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Ifosfamide.]
[L01CD01, paclitaxel, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Articaine.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ranibizumab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tocilizumab.]
[L01DC03, mitomycin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Mitomycin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Lidocaine.]
[L01AA05, mechlorethamine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Mechlorethamine.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Bevacizumab.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Mepivacaine.]
[L04AX03, methotrexate, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Methotrexate.]
[L01DB07, mitoxantrone, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Mitoxantrone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ofatumumab.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab.]
[L01CD02, docetaxel, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Docetaxel.]
[L01XX01, amsacrine, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Amsacrine.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Bevacizumab.]
[M05BA08, zoledronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Zoledronic acid.]
[L01XX08, pentostatin, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Pentostatin.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Edrecolomab.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Golimumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ustekinumab.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Canakinumab.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Procaine.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Bevacizumab.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Denosumab.]
[L01CD04, cabazitaxel, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cabazitaxel.]
[M05BA01, etidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.]
